Citations 2
Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis—ABCD-10
Rosenbach, Misha , Hubbard, Rebecca A. , Cardones, Adela R. , Chen, Jennifer K. , Cotliar, Jonathan , Davis, Mark D.P. , Fox, Lindy P., Hughey, Lauren C., Kaffenberger, Benjamin H. , Kroshinsky, Daniela , Kwong, Bernice Y. , Miller, Daniel D. , Musiek, Amy , Shinkai, Kanade , Summers, Erika M., Wetter, David A. , Worswick, Scott , Margolis, David J. , Kaffenberger, B , Noe, Megan H. , Mostaghimi, Arash , Dominguez, Arturo Ricardo , Ortega‐Loayza, Alex G. , Sharon, Victoria R. , Wanat, Karolyn A. , Gelfand, Joel M. , Micheletti, Robert
JAMA Dermatology | March 6, 2019 | Volume: 155 | Issue: 4 | Pages: 448
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia
Propert, Kathleen J., Loren, Alison W. , Paietta, Elisabeth , Sun, Zhuoxin , Levine, Ross L. , Straley, Kimberly, Yen, Katharine , Patel, Jay P., Agresta, Samuel , Abdel‐Wahab, Omar , Perl, Alexander E. , Litzow, Mark R. , Rowe, Jacob M. , Fernández, Hugo F. , Margolis, David J. , Tallman, Martin S. , Luger, Selina M. , DiNardo, Courtney D. , Lazarus, Hillard M. , Carroll, Martin P , Abdel-Wahab, Omar
Blood | May 3, 2013 | Volume: 121 | Issue: 24 | Pages: 4917-4924
Key Points Serum 2HG analysis by LC-MS can accurately identify patients with AML with and without IDH mutations. Oncometabolite testing of serum 2HG is indicated as a diagnostic, prognostic, and therapeutic monitoring tool in AML.